Cargando…

Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways

Sivelestat sodium (SIV), a neutrophil elastase inhibitor, is mainly used for the clinical treatment of acute respiratory distress syndrome (ARDS) or acute lung injury (ALI). However, studies investigating the effects of SIV treatment of ALI are limited. Therefore, this study investigated the potenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hong, Zeng, Jun, Li, Jiankang, Gong, Huankai, Chen, Meiling, Li, Quan, Liu, Shengxing, Luo, Shanjun, Dong, Huanxiang, Xu, Yingke, Duan, Huanling, Huang, Ling, Lv, Chuanzhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171443/
https://www.ncbi.nlm.nih.gov/pubmed/36724020
http://dx.doi.org/10.17305/bb.2022.8549
_version_ 1785039418977943552
author Zhang, Hong
Zeng, Jun
Li, Jiankang
Gong, Huankai
Chen, Meiling
Li, Quan
Liu, Shengxing
Luo, Shanjun
Dong, Huanxiang
Xu, Yingke
Duan, Huanling
Huang, Ling
Lv, Chuanzhu
author_facet Zhang, Hong
Zeng, Jun
Li, Jiankang
Gong, Huankai
Chen, Meiling
Li, Quan
Liu, Shengxing
Luo, Shanjun
Dong, Huanxiang
Xu, Yingke
Duan, Huanling
Huang, Ling
Lv, Chuanzhu
author_sort Zhang, Hong
collection PubMed
description Sivelestat sodium (SIV), a neutrophil elastase inhibitor, is mainly used for the clinical treatment of acute respiratory distress syndrome (ARDS) or acute lung injury (ALI). However, studies investigating the effects of SIV treatment of ALI are limited. Therefore, this study investigated the potential molecular mechanism of the protective effects of SIV against ALI. Human pulmonary microvascular endothelial cells (HPMECs) were stimulated with tumor necrosis factor α (TNF-α), and male Sprague–Dawley rats were intratracheally injected with Klebsiella pneumoniae (KP) and treated with SIV, ML385, and anisomycin (ANI) to mimic the pathogenetic process of ALI in vitro and in vivo, respectively. The levels of inflammatory cytokines and indicators of oxidative stress were assessed in vitro and in vivo. The wet/dry (W/D) ratio of lung tissues, histopathological changes, inflammatory cells levels in bronchoalveolar lavage fluid (BALF), and survival rates of rats were analyzed. The JNK/NF-κB (p65) and Nrf2/HO-1 levels in the HPMECs and lung tissues were analyzed by western blot and immunofluorescence analyses. Administration of SIV reduced the inflammatory factors levels, intracellular reactive oxygen species (ROS) production, and malondialdehyde (MDA) levels and increased the levels of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in lung tissues. Meanwhile, SIV alleviated pathological injuries, decreased the W/D ratio, and inflammatory cell infiltration in lung tissue. In addition, SIV also inhibited the activation of JNK/NF-κB signaling pathway, promoted nuclear translocation of Nrf2, and upregulated the expression of heme oxygenase 1 (HO-1). However, ANI or ML385 significantly reversed these changes. SIV effectively attenuated the inflammatory response and oxidative stress. Its potential molecular mechanism was related to the JNK/NF-κB activation and Nrf2/HO-1 signaling pathway inhibition. This further deepened the understanding of the protective effects of SIV against ALI.
format Online
Article
Text
id pubmed-10171443
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
record_format MEDLINE/PubMed
spelling pubmed-101714432023-06-01 Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways Zhang, Hong Zeng, Jun Li, Jiankang Gong, Huankai Chen, Meiling Li, Quan Liu, Shengxing Luo, Shanjun Dong, Huanxiang Xu, Yingke Duan, Huanling Huang, Ling Lv, Chuanzhu Biomol Biomed Research Article Sivelestat sodium (SIV), a neutrophil elastase inhibitor, is mainly used for the clinical treatment of acute respiratory distress syndrome (ARDS) or acute lung injury (ALI). However, studies investigating the effects of SIV treatment of ALI are limited. Therefore, this study investigated the potential molecular mechanism of the protective effects of SIV against ALI. Human pulmonary microvascular endothelial cells (HPMECs) were stimulated with tumor necrosis factor α (TNF-α), and male Sprague–Dawley rats were intratracheally injected with Klebsiella pneumoniae (KP) and treated with SIV, ML385, and anisomycin (ANI) to mimic the pathogenetic process of ALI in vitro and in vivo, respectively. The levels of inflammatory cytokines and indicators of oxidative stress were assessed in vitro and in vivo. The wet/dry (W/D) ratio of lung tissues, histopathological changes, inflammatory cells levels in bronchoalveolar lavage fluid (BALF), and survival rates of rats were analyzed. The JNK/NF-κB (p65) and Nrf2/HO-1 levels in the HPMECs and lung tissues were analyzed by western blot and immunofluorescence analyses. Administration of SIV reduced the inflammatory factors levels, intracellular reactive oxygen species (ROS) production, and malondialdehyde (MDA) levels and increased the levels of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in lung tissues. Meanwhile, SIV alleviated pathological injuries, decreased the W/D ratio, and inflammatory cell infiltration in lung tissue. In addition, SIV also inhibited the activation of JNK/NF-κB signaling pathway, promoted nuclear translocation of Nrf2, and upregulated the expression of heme oxygenase 1 (HO-1). However, ANI or ML385 significantly reversed these changes. SIV effectively attenuated the inflammatory response and oxidative stress. Its potential molecular mechanism was related to the JNK/NF-κB activation and Nrf2/HO-1 signaling pathway inhibition. This further deepened the understanding of the protective effects of SIV against ALI. Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2023-06-01 2023-05-01 /pmc/articles/PMC10171443/ /pubmed/36724020 http://dx.doi.org/10.17305/bb.2022.8549 Text en © 2023 Zhang et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Article
Zhang, Hong
Zeng, Jun
Li, Jiankang
Gong, Huankai
Chen, Meiling
Li, Quan
Liu, Shengxing
Luo, Shanjun
Dong, Huanxiang
Xu, Yingke
Duan, Huanling
Huang, Ling
Lv, Chuanzhu
Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways
title Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways
title_full Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways
title_fullStr Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways
title_full_unstemmed Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways
title_short Sivelestat sodium attenuates acute lung injury by inhibiting JNK/NF-κB and activating Nrf2/HO-1 signaling pathways
title_sort sivelestat sodium attenuates acute lung injury by inhibiting jnk/nf-κb and activating nrf2/ho-1 signaling pathways
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171443/
https://www.ncbi.nlm.nih.gov/pubmed/36724020
http://dx.doi.org/10.17305/bb.2022.8549
work_keys_str_mv AT zhanghong sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT zengjun sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT lijiankang sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT gonghuankai sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT chenmeiling sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT liquan sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT liushengxing sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT luoshanjun sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT donghuanxiang sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT xuyingke sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT duanhuanling sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT huangling sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways
AT lvchuanzhu sivelestatsodiumattenuatesacutelunginjurybyinhibitingjnknfkbandactivatingnrf2ho1signalingpathways